PT - JOURNAL ARTICLE AU - Heaney, Christopher D. AU - Pisanic, Nora AU - Randad, Pranay R. AU - Kruczynski, Kate AU - Howard, Tyrone AU - Zhu, Xianming AU - Littlefield, Kirsten AU - Patel, Eshan U. AU - Shrestha, Ruchee AU - Laeyendecker, Oliver AU - Shoham, Shmuel AU - Sullivan, David AU - Gebo, Kelly AU - Hanley, Daniel AU - Redd, Andrew D. AU - Quinn, Thomas C. AU - Casadevall, Arturo AU - Zenilman, Jonathan M. AU - Pekosz, Andrew AU - Bloch, Evan M. AU - Tobian, Aaron A. R. TI - Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers AID - 10.1101/2021.01.28.21250717 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.28.21250717 4099 - http://medrxiv.org/content/early/2021/02/01/2021.01.28.21250717.short 4100 - http://medrxiv.org/content/early/2021/02/01/2021.01.28.21250717.full AB - Oral fluid (hereafter saliva) offers a non-invasive sampling method for the detection of SARS-CoV-2 antibodies. However, data comparing performance of salivary tests against commercially-available serologic and neutralizing antibody (nAb) assays are lacking. This study compared the performance of a multiplex salivary SARS-CoV-2 IgG assay targeting antibodies to nucleocapsid (N), receptor binding domain (RBD) and spike (S) antigens to three commercially-available SARS-CoV-2 serology enzyme immunoassays (EIAs) (Ortho Vitros, Euroimmun, and BioRad) and nAb. Paired saliva and plasma samples were collected from 101 eligible COVID-19 convalescent plasma (CCP) donors >14 days since PCR+ confirmed diagnosis. Concordance was evaluated using positive (PPA) and negative (NPA) percent agreement, overall percent agreement (PA), and Cohen’s kappa coefficient. The range between salivary and plasma EIAs for SARS-CoV-2-specific N was PPA: 54.4-92.1% and NPA: 69.2-91.7%, for RBD was PPA: 89.9-100% and NPA: 50.0-84.6%, and for S was PPA: 50.6-96.6% and NPA: 50.0-100%. Compared to a plasma nAb assay, the multiplex salivary assay PPA ranged from 62.3% (N) and 98.6% (RBD) and NPA ranged from 18.8% (RBD) to 96.9% (S). Combinations of N, RBD, and S and a summary algorithmic index of all three (N/RBD/S) in saliva produced ranges of PPA: 87.6-98.9% and NPA: 50-91.7% with the three EIAs and ranges of PPA: 88.4-98.6% and NPA: 21.9-34.4% with the nAb assay. A multiplex salivary SARS-CoV-2 IgG assay demonstrated comparable performance to three commercially-available plasma EIAs and a nAb assay, and may be a viable alternative to assist in screening CCP donors and monitoring population-based seroprevalence and vaccine antibody response.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis was an assay development and validation study, not a clinical trial.Funding StatementThis work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID) (O.L., A.D.R., T.C.Q.), as well as extramural support from NIAID (R01AI120938, R01AI120938S1 and R01AI128779 to A.A.R.T; R01AI05273 and R01AI152078 to A.C.; T32AI102623 for supporting E.U.P.; and NIH Center of Excellence in Influenza Research and Surveillance HHSN272201400007C to A.P.), National Heart Lung and Blood Institute (K23HL151826 to E.M.B and R01HL059842 to A.C.), Bloomberg Philanthropies (A.C.) and Department of Defense (W911QY2090012 to D.S.), Johns Hopkins COVID-19 Research and Response Program, the FIA Foundation, a gift from the GRACE Communications Foundation (C.D.H., P.R.R., N.P., K.K.), NIAID grants R21AI139784 (C.D.H. and N.P), National Institute of Environmental Health Sciences (NIEHS) grant R01ES026973 (C.D.H., N.P., K.K.), NIAID grant R01AI130066 and NIH grant U24OD023382 (C.D.H), and NIH grant from NCATS U24TR001609 (D.H.). The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used stored samples and data from two parent studies that were approved by The Johns Hopkins University School of Medicine Institutional Review Board. All samples were de-identified prior to laboratory testing, and all participants provided informed consent. Both studies were conducted according to the ethical standards of the Helsinki Declaration of the World Medical Association.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA de-identified dataset may be made available upon request.